Gossamer Bio, Inc.
GOSS
$1.25
$0.075.93%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 9.38M | 9.48M | 95.84M | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.38M | 9.48M | 95.84M | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 9.38M | 9.48M | 95.84M | -- | -- |
| SG&A Expenses | 9.40M | 8.50M | 8.67M | 9.57M | 9.06M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 45.51M | 43.40M | 43.76M | 41.96M | 39.03M |
| Operating Income | -36.13M | -33.92M | 52.09M | -41.96M | -39.03M |
| Income Before Tax | -35.44M | -31.94M | 53.67M | -41.93M | -48.15M |
| Income Tax Expenses | -2.41M | -1.13M | 4.44M | -- | -- |
| Earnings from Continuing Operations | -33.03M | -30.80M | 49.23M | -41.93M | -48.15M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -33.03M | -30.80M | 49.23M | -41.93M | -48.15M |
| EBIT | -36.13M | -33.92M | 52.09M | -41.96M | -39.03M |
| EBITDA | -36.02M | -33.70M | 52.34M | -41.70M | -38.74M |
| EPS Basic | -0.29 | -0.14 | 0.22 | -0.19 | -0.21 |
| Normalized Basic EPS | -0.27 | -0.09 | 0.15 | -0.12 | -0.13 |
| EPS Diluted | -0.29 | -0.14 | 0.22 | -0.19 | -0.21 |
| Normalized Diluted EPS | -0.27 | -0.09 | 0.14 | -0.12 | -0.13 |
| Average Basic Shares Outstanding | 226.60M | 226.35M | 226.22M | 225.74M | 225.41M |
| Average Diluted Shares Outstanding | 226.60M | 226.35M | 238.54M | 225.74M | 225.41M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |